U.S. Department of Health and Human Services
Phillip Gorden
 

 Contact Info

 
Tel: 301-402-7340
Email: gordenp@extra.niddk.nih.gov
 

 Select Experience

 
  • M.D.Vanderbilt University School of Medicine1961
  • B.A.Vanderbilt University1957
 

 Related Links

 

    ​

    Phillip Gorden, M.D.

    Senior Investigator, Diabetes, Endocrinology, and Obesity BranchClinical and Cellular Biology Section
    Director Emeritus, Office of the Director
    Specialties
    • Clinical Research

    ​Publications

    A selection of recent and significant publications can be viewed below.

    Publications
    Butler PW, Cochran CS, Merino MJ, Nguyen DM, Schrump DS, Gorden P. Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy. Pituitary. 2012 Jun; 15:260-5. [Full Text/Abstract]
    Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 2012 Feb; 97:563-7. [Full Text/Abstract]
    Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resistance. Endocr. Rev. 2011 Aug; 32:498-514. [Full Text/Abstract]
    Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010 Feb; 6:229-37. [Full Text/Abstract]
    Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine (Baltimore). 2009 May; 88:141-53. [Full Text/Abstract]
    Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J. Clin. Invest. 2009 Feb; 119:315-22. [Full Text/Abstract]
    Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P, O'Rahilly S. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care. 2008 May; 31:977-9. [Full Text/Abstract]
    Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O'Rahilly S, Balow JE, Gorden P. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J. Clin. Endocrinol. Metab. 2004 Jul; 89:3199-207. [Full Text/Abstract]
    Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004 Jul; 83:209-22. [Full Text/Abstract]
    Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J. Clin. Endocrinol. Metab. 2004 Apr; 89:1548-54. [Full Text/Abstract]
    Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, Gorden P. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J. Clin. Endocrinol. Metab. 2002 Jul; 87:3110-7. [Full Text/Abstract]
    Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002 Mar; 81:87-100. [Full Text/Abstract]
    Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 2002 Feb 21; 346:570-8. [Full Text/Abstract]
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011 Nov-Dec; 17:922-32. [Full Text/Abstract]